Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTUR: Targeted Agent Utilization Trial
NCT03297606Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Mar 2018
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of axitinib, bosutinib, crizotinib, dasatinib, erlotinib and 12 more in solid tumor (advanced stage), multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) (14 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Objective Response Rate at 4 years. Started Mar 2018; status: recruiting.
02
Drugs
axitinibbosutinibcrizotinibdasatiniberlotinib
03
Conditions
solid tumor (advanced stage)multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03297606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297606.